BNTX
HealthcareBioNTech SE
$96.85
+$0.16 (+0.17%)
Jan 5, 2026
Price History (1Y)
Analysis
BioNTech SE is a biotechnology company listed on the healthcare sector with a market capitalization of $23.29 billion. The company operates in the biotechnology industry and has a significant scale, employing 6,772 people. Financially, BioNTech SE reported revenue of $3.15 billion for the trailing twelve months, with a gross margin of 82.5%. However, the company has incurred net losses, with a net income of -$571 million for the same period. Additionally, the operating margin was -2.2% and the profit margin was -18.1%. The company's returns on equity (ROE) and return on assets (ROA) were -3.0% and -2.3%, respectively. BioNTech SE has a debt-to-equity ratio of 1.33, with cash reserves of $14.53 billion and total debt of $245 million. The company's valuation is characterized by a forward P/E ratio of -35.16, which indicates significant losses for the trailing twelve months. The price to book ratio was 1.08, while the price to sales ratio stood at 7.39. Revenue growth has been strong, with a year-over-year (YoY) increase of 22%. However, earnings growth data is not available.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Visit website →Key Statistics
- Market Cap
- $23.29B
- P/E Ratio
- N/A
- 52-Week High
- $129.27
- 52-Week Low
- $81.20
- Avg Volume
- 1.04M
- Beta
- 1.41
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- Germany
- Employees
- 6,772